Neovia reports efficacy data to FDA

In its 2019 annual IND update to USA FDA, Neovia has reported progress for the continuing phase I(a) dose escalation trial for its lead compound NEV-801. Neovia reported safe dose escalation from 20mg/m2 to 240mg/m2 with no serious adverse events attributable to the investigational drug. Although efficacy is not the prime objective of a dose-escalation phase, 32% disease stabilization and 15% partial response in aggressive, advanced tumors such as ovarian, colon, and pancreatic cancers were also reported. Cohort 7 of the dose-escalation phase is underway in 2020 with a dose of 320mg/m2